A Study Comparing the Efficacy and Safety of Ziprasidone and Aripiprazole for the Treatment fo Schizophrenia or Schizoaffective Disorder in Hospitalized Patients

• Status: Completed
• Trial end date: 2005-03-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to compare the efficacy and safety of ziprasidone and aripiprazole in hospitalized patients with schizophrenia or schizoaffective disorder

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Pfizer; Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
• Treatments: Aripiprazole; Ziprasidone

Criteria

Inclusion Criteria:

• Hospitalized patients with schizophrenia or schizoaffective disorder

• At least a 6th grade reading level

• Males or females, between 18 and 70 years of age at the time of consent

• Subjects must have been hospitalized for no more than 14 consecutive days immediately prior to screening

Exclusion Criteria:

• Psychiatric disorder other than schizophrenia or schizoaffective disorder

• History of arrhythmia, heart attack, or heart failure